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Introduction
Colorectal carcinoma (CRC) is the second leading cause of malignancy in Western countries, accounting for 151 000 new cases and 61 000 deaths annually in the USA. 1 In Japan its incidence has been increasing rapidly over the last 20 years and it is now the most common malignancy, after gastric cancer, accounting for 30 000 deaths per year. In spite of intensive efforts, there is still no satisfactory treatment that significantly improves the overall survival rate of patients with CRC. 2 A significant number of patients die from recurrent disease, with the liver being the most common site for metastases. Peritoneal metastasis is the next most frequent type of recurrence and also a serious obstacle to the curative treatment of CRC. 3, 4 Gene therapy could provide an innovative therapeutic approach for the treatment of CRC. Among various strategies for gene therapy against cancer, the delivery of a suicide gene into tumor cells followed by the corresponding prodrug treatment, such as the combination of Escherichia coli cytosine deaminase (CD) gene transduction and 5-fluorocytosine (5-FC) treatment, is one of the most promising approaches. CD is an enzyme found in many bacteria and fungi which deaminates cytosine to uracil, while normal mammalian cells do not possess CD. It also deaminates the relatively nontoxic 5-FC to the highly toxic 5-fluorouracil (5-FU). 5-FU has been used most commonly for the treatment of CRC, alone or in combination with other chemotherapeutic agents. It causes cell death by inhibiting both DNA and RNA syntheses. 5 However, its effectiveness is limited by systemic toxicity specifically associated with high doses. In marked contrast to 5-FU, which has a narrow therapeutic index, 5-FC is not toxic to humans at therapeutic doses. 6 It is, therefore, desirable to produce a high local concentration of 5-FU at the tumor site. Localized in vivo generation of 5-FU as a novel strategy for antitumor therapy was reported by Nishiyama et al. 7 They implanted capsules containing CD into subcutaneous tumors growing in rats. This was followed by systemic administration of 5-FC. Considerable antitumor activity without observable toxic effects was evident using this approach. With the advancement of recombinant DNA techniques, a similar strategy was recently implemented using a genetic approach. Mullen et al 8 and Huber et al 9 genetically modified tumor cells to express CD. They implanted the modified cells into mice and demonstrated local 5-FU generation and antitumor effects. Expression of the CD gene has been achieved recently in various cell lines, such as fibrosarcoma, adenocarcinoma including CRC lines, gliosarcoma and hepatocellular carcinoma. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Those genetically modified cells were selectively sensitive to 5-FC compared with unmodified cells. Therefore, transfer of the CD gene followed by 5-FC treatment could be a promising approach for various types of cancer, if tumor cell-selective transduction or expression of the CD gene could be feasible in vivo.
CEA is a M r 180 000 cell surface glycoprotein originally described by Gold and Freedman 21 as an antigenic component in cancers derived from gastrointestinal tract epithelium. Although later studies have shown that CEA is also expressed on the apical surface of epithelial cells in the normal colon, 22 ,23 levels of its expression are usually much higher in malignant colon and other cancers of epithelial cell origin compared with normal adult colon. Therefore, by coupling the CEA promoter with the CD gene, CD gene expression is expected to be restricted to tumor cells that produce high levels of CEA. 16 Consequently, in the presence of 5-FC, a high local concentration of 5-FU can be produced in the CEA-producing tumor to kill tumor cells, while sparing the surrounding normal tissues.
We have recently isolated CEA promoter regions from high CEA-producing human CRC. 24 In the present study, we have constructed retrovirus vectors carrying the bacterial CD gene under the transcriptional control of the CEA promoter regions. This study examined whether infection of retroviruses carrying the CD gene under the control of the CEA promoter regions can cause killing of CEA-producing tumor cells without affecting CEA-nonproducing cells in the presence of 5-FC. Furthermore, to examine the antitumor effect against advanced CRC, athymic nude mice were inoculated intraperitoneally with CEA-producing human CRC cells and retrovirusproducing cells. Using this animal model, the efficacy and safety of using the Moloney murine leukemia virus long terminal repeat promoter and CEA promoter to direct CD gene expression were examined.
Results

CEA production ability of tumor cells
To estimate the specificity of the CEA promoter regions, it is necessary to identify and rank CEA-positive and CEA-negative cell lines. Previous studies have shown a correlation between CEA protein levels and CEA transcription. [25] [26] [27] It has been also shown that most of the CEA protein is secreted into the medium. 16 CEA protein concentrations of media were, therefore, quantified by using immunoassay to evaluate transcriptional levels of the CEA gene in the cells used in experiments. As shown in Table 1 , human CRC LoVo and SW1463 cells were shown to produce considerably high levels of the CEA protein. Conversely, human renal cell carcinoma RC9406 cells, human cervix carcinoma HeLa cells and human hepatocellular carcinoma SMMC7721 cells were shown not to produce detectable levels of the CEA protein.
Sensitivity to 5-FC of cells transduced with the CD gene CEA promoter regions isolated from high CEA-producing human colorectal carcinoma, located from −309 to +110 bp and from −135 to +69 bp upstream from the transcriptional start site of the CEA gene, were employed to direct the CD gene expression in a retrovirus vector ( Figure 1 ). Before estimating the sensitivity to 5-FC, the sensitivity to 5-FU of the cell lines was assessed. As shown in Table 1 from −135 to +69 bp upstream from the transcriptional start site of the CEA gene. However, the IC 50 value to 5-FC for CEA419/CD retrovirus-infected RC9406 cells was significantly higher than that for CEA204/CD retrovirusinfected ones. Furthermore, 5-FC IC 50 values for CEA419/CD retrovirus-infected HeLa and SMMC7721 cells were also higher than those for the corresponding CEA204/CD retrovirus-infected ones, although the differences were not statistically significant at P = 0.052 and 0.053, respectively, using Student's t test. These results suggest that the CEA promoter region located from −309 to +110 bp upstream from the transcriptional start site can induce CEA-producing cell-selective expression of exogenous genes more stringently compared with the CEA promoter region located from −135 to +69 bp upstream from the transcriptional start site.
In vivo sensitivity of CD gene-transduced CRC to 5-FC To examine in vivo sensitivity of CD gene-transduced CRC to 5-FC, CRC xenograft experiments were performed. Parental, CEA204/CD retrovirus-infected or pCD2 retrovirus-infected LoVo cells were inoculated subcutaneously into the flank regions of athymic BALB/cnu/nu mice. Twenty-five days after inoculation, mice received intraperitoneal injections of 5-FC or PBS for 7 consecutive days. As shown in Figure 2 , there were no significant differences in tumor volume among the groups at the time of initiation of 5-FC or PBS treatment, and mean tumor volume of each group was between 88 mm 3 and 102 mm 3 . Mice inoculated with parental LoVo cells and treated with 5-FC developed rapidly growing tumors. Similarly, mice inoculated with CEA204/CD retrovirus-infected LoVo cells and treated with PBS also developed rapidly growing tumors. All animals in these groups died or were killed due to tumor overloading within 60 days after the inoculation. Conversely, tumors of the mice inoculated with CEA204/CD or pCD2 retrovirus-infected cells followed by 5-FC treatment grew slowly until day 40, and then did not grow significantly or were even reduced. All animals in these two groups stayed alive over a 60-day observation per- iod. After the end of the observation period, all animals inoculated with CEA204/CD or pCD2 retrovirus-infected LoVo cells followed by 5-FC treatment were killed and subcutaneous tumors were resected for routine histology. Consistent with the previous report, 12 significant necrotic and fibrotic areas with infiltration of fibrocytes and lymphocytes were evident in all the resected tumors. There were no apparent differences between 5-FC-treated tumors consisting of CEA204/CD and pCD2 retrovirusinfected LoVo cells (data not shown).
Therapeutic effect on disseminated CRC by in vivo gene therapy
To investigate the efficacy of in vivo gene therapy using the CEA promoter regions to direct the CD gene on established tumors, an animal model with intraperitoneally disseminated LoVo tumors that closely resemble human advanced CRC was used. Athymic nude mice received an intraperitoneal inoculation of LoVo cells. PA317 retrovirus-packaging cells, CEA419/CD retrovirus-producing cells or pCD2 retrovirus-producing cells were injected intraperitoneally at days 3, 5 and 7 after the inoculation of LoVo cells. 5-FC, 5-FU or PBS was administered intraperitoneally from day 10 to day 16. Figure 3 shows the survival rates of animals after the inoculation of LoVo cells. All the mice that received intraperitoneal injections of 5-FU without receiving injections of retrovirus-producing cells died within 18 days. All the mice injected with PA317 retrovirus-packaging cells followed by 5-FC treatment and all the mice injected with CEA419/CD retrovirus-producing cells followed by PBS treatment died within 20 and 25 days, respectively. Conversely, the survival rate of mice injected with pCD2 retrovirus-producing cells followed by 5-FC treatment was significantly higher compared with those mice in the above-men- tioned groups, and the last mouse died 50 days after inoculation with LoVo cells. Furthermore, the survival rate of mice injected with CEA419/CD retrovirus-producing cells followed by 5-FC treatment was significantly higher than that of mice injected with pCD2 retrovirusproducing cells followed by 5-FC treatment, and 70% of the mice were still alive even 50 days after inoculation with LoVo cells.
Treatment-related bone marrow suppression
To examine the treatment-related cytotoxicity on the bone marrow, athymic nude mice were inoculated intraperitoneally with LoVo cells and received the treatment as described above. Animals were killed 17 days after inoculation with LoVo cells and bone marrow tissues from femora and sterna were examined. To examine the treatment-related bone marrow suppression, ratios of karyocytes:mature erythrocytes (K:E) in the bone marrow were estimated. Naive BALB/c-nu/nu mice have relatively high K:E ratios compared with humans, and their K:E ratios generally range from 60% to 70%. As shown in Figure 4 , K:E ratios of the mice injected with CEA419/CD retrovirus-producing cells followed by PBS treatment were not affected, while those of the mice treated with 5-FU were profoundly suppressed, with mean K:E ratios in the bone marrow of femora and sterna being 3% and 2%, respectively. Significant bone marrow suppression was not observed in the mice injected with CEA419/CD retrovirus-producing cells followed by 5-FC treatment, with mean K:E ratios in the bone marrow of femora and sterna being 62% and 57%, respectively. Conversely, the bone marrow of the mice injected with pCD2 retrovirusproducing cells followed by 5-FC treatment was mark- edly suppressed, with K:E ratios in the bone marrow of femora and sterna being 5% and 7%, respectively.
Discussion
To achieve effective and safe in vivo gene therapy for cancer using suicide genes, it is necessary to induce strong, tumor-selective expression of suicide genes. Because tumor-selective receptor-mediated vector delivery systems have not been established, the use of tumor-selective promoters, such as a CEA promoter and ␣-fetoprotein promoter, to direct expression of suicide genes is the most promising alternative. It has been shown already that the CEA promoter isolated from a human genomic library can induce tumor-selective expression of exogenous genes in human CRC, 16 gastric cancer 28, 29 and lung cancer, 30 in which CEA is highly produced. Recently, we have isolated CEA promoter regions consisting of 419 bp and 204 bp from a high CEA-producing human CRC, and demonstrated that they can direct more than 20-fold higher expression of a luciferase reporter gene in CEAproducing CRC cells compared with CEA-nonproducing cells. 24 Furthermore, in CEA-producing CRC cells, the CEA promoter regions were shown to be as active as the SV40 enhancer/promoter, which has been used as a general, strong promoter to direct expression of therapeutic genes. 24 Richards et al 16 have demonstrated that the CEA promoter is located between −90 and +69 bp upstream from the transcriptional start site. Chen et al 31 have also demonstrated that the CEA promoter region between −123 and −28 bp upstream from the transcriptional start site contains binding sites for several important trans-acting factors such as Sp-1 and upstream stimulatory factor. We have isolated CEA promoter regions including the core sequences from a high CEA-producing human CRC and linked them with the bacterial CD gene. Upstream regions of the CEA gene located between −309 and +110 bp and between −135 and +69 bp upstream from the transcriptional start site were found to be able to direct CEAproducing cell-selective CD gene expression, resulting in 20-to 27-fold higher susceptibility to 5-FC compared with the corresponding parental cells. There was a tendency for the CEA promoter region between −309 and +110 bp to induce more stringent killing of CEA-producing cells than that between −135 and +69 bp, indicating that the 5′ flanking region of the CEA gene between −309 and −135 bp may contain some sequences that provide CEAproducing cell-selective gene expression.
As shown previously, 12,14,16,17,32 established subcutaneous CRCs composed of CD gene-transduced cells were susceptible to systemic 5-FC treatment. It should be stressed that the bulk of G418-selected cells were used as CD gene-transduced cells in the present study, although the best CD gene-transduced clone was used in much of the literature. Therefore, the results demonstrated here may be more realistic when gene therapy using the CD gene is employed in a clinical setting. CRCs consisting of bulky CD gene-transduced cells exhibited an approximately two-fold reduction by 5-FC treatment compared with controls and did not grow or were even reduced thereafter. Previous in vivo studies have shown that the host's immune responses play an important role in the antitumor effects caused by the CD/5-FC system. 15, 32 Although athymic nude mice do not possess an intact T cell system, they have T cell-independent immune systems, such as natural killer cells. Therefore, it is possible that while CD gene-transduced CRC cells were continuously eliminated by 5-FC treatment, T cell-independent immune responses against CRC cells were elicited in nude mice, resulting in growth arrest or even reduction of CRC.
For gene therapy to be a promising clinical modality for the treatment of CRC, it is essential to target tumor cells, while sparing other normal cells. We have shown here that transduction of the CD gene under the transcriptional control of the CEA promoter makes CEA-producing CRC cells susceptible to 5-FC without affecting the sensitivity to 5-FC of CEA-nonproducing cells. Hirschowitz et al 14 have demonstrated the efficacy on CRC of adenovirus-mediated in vivo transduction of the CD gene directed by a CEA promoter followed by 5-FC treatment. In their studies, animals inoculated subcutaneously with CRC cells were used as an in vivo CRC model, which is apparently different from clinical manifestations. Therefore, we used an animal model bearing CRC cells intraperitoneally to imitate human advanced disseminated CRCs. Retrovirus-mediated in vivo transduction of the CD gene was shown to confer susceptibility to 5-FC on intraperitoneally disseminated CEA-producing CRCs. Significantly prolonged survival periods were observed in animals bearing disseminated CRCs by intraperitoneal injections of pCD2 or CEA419/CD retrovirus-producing cells followed by 5-FC treatment. Importantly, the survival rate of animals injected with CEA419/CD retrovirus-producing cells was significantly higher than that of animals injected with pCD2 retrovirus-producing cells.
Another important concern as well as efficacy is safety of the treatment, because safety is a major issue for the clinical application of gene therapy. Retroviruses possess the ability of selectively infecting and achieving integration into the genome of dividing cells. 33 Retroviruses are, therefore, an attractive vector for tumor-selective gene transfer, because most normal cells surrounding cancers are in a quiescent, nonreceptive stage of cell growth. There are, however, noncancerous normal dividing cells, such as bone marrow cells. In the intraperitoneally disseminated CRC experiments, six of 10 animals injected with pCD2 retrovirus-producing cells followed by 5-FC treatment and eight of 10 animals treated with 5-FU died without massively disseminated CRCs. Subsequent experiments revealed that systemic administration of 5-FC caused severe bone marrow suppression in animals injected intraperitoneally with pCD2 retrovirus-producing cells. Conversely, significant bone marrow suppression was not observed in animals injected with CEA419/CD retrovirus-producing cells followed by 5-FC treatment. These results may indicate that the death of animals with pCD2 retrovirus-producing cells followed by 5-FC treatment was due to the tumor-burden and bone marrow suppression, while the death of animals injected with CEA419/CD retrovirus-producing cells followed by 5-FC treatment was due to the tumor burden. These results may imply the safety of gene therapy with CEA promoter-directed CD gene and 5-FC treatment.
To prove the usefulness of the strategy using in vivo transduction of the CEA promoter-directed CD gene followed by 5-FC treatment against human CRC, more investigations have to be performed. Specifically, better vectors have to be developed, because current vectors, such as liposomes, retroviruses and adenoviruses, have their own limitations for clinical application. The results demonstrated here, however, indicate the potential efficacy and safety of transferring the CD gene directed by the CEA promoter in vivo followed by systemic administration of 5-FC for the treatment of patients with CRCs.
Materials and methods
Cell lines and cell culture Human colorectal carcinoma cell line LoVo and SW1463, human cervix carcinoma cell line HeLa, murine embryo fibroblast cell line NIH3T3, ecotropic retrovirus-packaging cell line Psi2 and amphotropic retrovirus-packaging cell line PA317 were purchased from the American Type Culture Collection (Rockville, MD, USA). Human hepatocellular carcinoma cell line SMMU7721 and human renal cell carcinoma cell line RC9406 were established by the Departments of Pathology and Microbiology of the Second Military Medical University (Shanghai, China), respectively. The cells were grown in RPMI 1640 medium containing 10% heat-inactivated fetal calf serum, 100 units/ml ampicillin and 100 mg/ml streptomycin at 37°C in a humidified 5% CO 2 atmosphere.
CEA secretion of cells was measured following a 7-day accumulation using the CEA-EIA Monoclonal One-step kit (Abbott Laboratories, Abbott, IL, USA). CEA expression was standardized based on the protein content of cell pellets using the BioRad protein assay kit (Hercules, CA, USA).
Construction of retrovirus vectors
Construction of CR4Ca-CEA419/LUC and CR4Ca-CEA204/LUC plasmids, which contain a luciferase reporter gene under the transcriptional control of the CEA promoter regions isolated from a high CEA-producing human colorectal carcinoma, has been described elsewhere. Recombinant retrovirus production CEA419/CD and CEA204/CD retrovirus vector constructs were converted to the corresponding retroviruses by the transinfection protocol. The retrovirus vector constructs were transfected by using LipofectAMINE Reagent (Gibco BRL, Grand Island, NY, USA) according to the protocol provided by the manufacturers into the ecotropic retrovirus-packaging cell line Psi2, as described previously. 35 Filtered supernatants from ecotropic retrovirus-producing cells were then added to the amphotropic retrovirus-packaging cell line PA317 in the presence of 8 g/ml Polybrene (Sigma Chemical, St Louis, MO, USA). After 48 h, the cells were split and plated in the medium containing 400 g/ml active G418 (Gibco BRL). Individual G418-resistant clones were isolated by cloning cylinders and tested for ability to produce recombinant retroviruses. The titers of recombinant viral particles were determined by infecting NIH3T3 cells with serial dilutions of the culture medium from each clone, as described previously. 36 The high-titer retrovirus-producing clones selected for subsequent experiments had titers of approximately 1 × 10 6 colony-forming units/ml as assayed by G418 selection of infected NIH3T3 cells. The culture supernatant of the high-titer retrovirus-producing clones was collected, passed through a 0.45-m pore filter (Millipore, Bedford, MA, USA), and stored at −70°C. It served as a source for infectious recombinant retroviruses. pCD2 retrovirus-producing clones with titers of approximately 1 × 10 6 colony-forming units/ml were also established in a similar manner and used for subsequent experiments.
In vitro gene transfer
Freshly prepared cells were infected with the recombinant retroviruses at 37°C, 5% CO 2 for 4-6 h in the medium containing 8 g/ml polybrene, as described previously. 37 Retrovirus-infected cells were selected by addition of 400 g/ml active G418, and the bulk of G418-resistant cells were expanded and used as retrovirusinfected cells for subsequent experiments.
Evaluation of in vitro sensitivity to 5-FC Cells were plated at a density of 1 × 10 3 cells per well in 96-well, flat-bottomed tissue culture plates in the media containing various concentrations (100 m-50 000 m) of 5-FC (Sigma). The cells were then cultured at 37°C for 4 days and the number of viable cells was measured using the MTT assay as described previously. 36 The IC 50 for each cell line was calculated using a curve-fitting parameter based on the Marquardt method. 38 Sensitivity of cells to 5-FU was also estimated by a similar manner.
Antitumor effect by CD/5-FC system To examine the in vivo sensitivity of CD gene-transduced cells to 5-FC, parental, pCD2 retrovirus-infected and CEA204/CD retrovirus-infected LoVo cells were suspended in the serum-free RPMI 1640 medium at a concentration of 2 × 10 7 cells/ml, and 200-l inoculum volumes were injected subcutaneously into the flank regions of female athymic BALB/c-nu/nu mice, purchased from the Experimental Animal Center (Shanghai, China). 5-FC (700 mg/kg body weight/day) was administered intraperitoneally, 25 days later, for 7 consecutive days, to animals inoculated with parental or pCD2 retrovirusinfected LoVo cells. Animals inoculated with CEA204/CD retrovirus-infected LoVo cells had 5-FC or PBS administered intraperitoneally for 7 days. Each group consisted of five animals. Tumor development was observed for 60 days and tumor volume was calculated every 2 or 3 days according to the formula: V (mm 3 ) = A (mm) × B (mm) 2 /2 (A = largest diameter; B = smallest diameter). Animals were killed before the end of the observation period when they developed excessively large tumors or when there were other signs of animal distress. All animal experiments were performed using approved protocols and in accordance with recommendations for the proper care and use of laboratory animals.
In vivo gene therapy for disseminated CRC To examine the therapeutic effects of in vivo CD gene transduction by means of retrovirus vectors followed by 5-FC treatment on disseminated CRCs, athymic BALB/cnu/nu mice received an intraperitoneal inoculation of 2 × 10 6 parental LoVo cells suspended in 200 l of the serum-free medium and divided randomly 3 days later into the following five groups according to treatment schedules: (a) injection of PA317 retrovirus-packaging cells followed by 5-FC treatment (n = 10); (b) injection of pCD2 retrovirus-producing cells followed by 5-FC treatment (n = 10); (c) injection of CEA419/CD retrovirus-producing cells followed by 5-FC treatment (n = 10); (d) injection of CEA419/CD retrovirus-producing cells followed by PBS treatment (n = 10); (e) injection of the serum-free medium followed by 5-FU treatment (n = 10). In groups (a) to (d), 2 × 10 6 PA317 retrovirus-packaging cells, pCD2 retrovirus-producing cells and CEA419/CD retrovirus-producing cells were suspended in 200 l of the serum-free medium containing 16 g/ml polybrene and injected intraperitoneally into mice at days 3, 5 and 7 after the intraperitoneal inoculation of LoVo cells. In group (e), 200 l of the serum-free medium containing 16 g/ml polybrene were injected intraperitoneally into mice at days 3, 5 and 7. 5-FC (700 mg/kg body weight/day), 5-FU (500 mg/kg body weight/day) or PBS was then administered intraperitoneally to animals from day 10 to day 16. Survival of animals was observed everyday.
Evaluation of bone marrow suppression by the CD/5-FC system An animal model with intraperitoneally disseminated CRCs was produced and treated as described above. Animals were killed on the day after termination of 5-FC, 5-FU or PBS administration. Bone marrow was extracted from the femur of each mouse, smeared quickly on a glass slide, dried with a fan and fixed with methanol for 5 to 10 min. The slides were then stained with a mixture of Giemsa and Wright staining solutions containing methylene blue, eosin, azure, methanol and glycerol for 30 min. To examine the bone marrow suppression, karyocytes, referred to cells with nuclei, and mature erythrocytes were counted under a microscope and K:E ratios were calculated. Bone marrow was also extracted from the sternum of each mouse, fixed in 10% buffered formalin, embedded in paraffin and serially sectioned. K:E ratios were determined five times for each mouse.
Statistics
Results are expressed as means ± s.d. Standard descriptive statistics, Student's t test and the 2 test, were used. A P value of Ͻ0.05 was considered to indicate a significant difference between groups.
